vs
RPC INC（RES）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是RPC INC的1.8倍（$772.1M vs $425.8M），Revvity净利率更高（12.7% vs -0.7%，领先13.5%），RPC INC同比增速更快（27.0% vs 5.9%），Revvity自由现金流更多（$161.8M vs $31.2M），过去两年Revvity的营收复合增速更高（9.0% vs 6.2%）
RPC集团是总部位于英国的企业，曾是欧洲规模最大的塑料包装供应商之一，总部坐落于北安普敦郡的拉什登。该公司此前在伦敦证券交易所上市，2019年被贝瑞全球集团收购，贝瑞全球集团又于2025年被安海斯包装收购。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
RES vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.8倍
$425.8M
营收增速更快
RES
高出21.1%
5.9%
净利率更高
RVTY
高出13.5%
-0.7%
自由现金流更多
RVTY
多$130.6M
$31.2M
两年增速更快
RVTY
近两年复合增速
6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $425.8M | $772.1M |
| 净利润 | $-3.1M | $98.4M |
| 毛利率 | 21.0% | — |
| 营业利润率 | -0.9% | 14.5% |
| 净利率 | -0.7% | 12.7% |
| 营收同比 | 27.0% | 5.9% |
| 净利润同比 | -124.0% | 3.9% |
| 每股收益（稀释后） | $-0.02 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RESRVTY
| Q4 25 | $425.8M | $772.1M | ||
| Q3 25 | $447.1M | $698.9M | ||
| Q2 25 | $420.8M | $720.3M | ||
| Q1 25 | $332.9M | $664.8M | ||
| Q4 24 | $335.4M | $729.4M | ||
| Q3 24 | $337.7M | $684.0M | ||
| Q2 24 | $364.2M | $691.7M | ||
| Q1 24 | $377.8M | $649.9M |
净利润RESRVTY
| Q4 25 | $-3.1M | $98.4M | ||
| Q3 25 | $13.0M | $46.7M | ||
| Q2 25 | $10.1M | $53.9M | ||
| Q1 25 | $12.0M | $42.2M | ||
| Q4 24 | $12.8M | $94.6M | ||
| Q3 24 | $18.8M | $94.4M | ||
| Q2 24 | $32.4M | $55.4M | ||
| Q1 24 | $27.5M | $26.0M |
毛利率RESRVTY
| Q4 25 | 21.0% | — | ||
| Q3 25 | 25.1% | 53.6% | ||
| Q2 25 | 24.5% | 54.5% | ||
| Q1 25 | 26.7% | 56.5% | ||
| Q4 24 | 25.4% | — | ||
| Q3 24 | 26.7% | 56.3% | ||
| Q2 24 | 28.0% | 55.7% | ||
| Q1 24 | 26.8% | 54.6% |
营业利润率RESRVTY
| Q4 25 | -0.9% | 14.5% | ||
| Q3 25 | 4.7% | 11.7% | ||
| Q2 25 | 3.7% | 12.6% | ||
| Q1 25 | 3.7% | 10.9% | ||
| Q4 24 | 3.1% | 16.3% | ||
| Q3 24 | 5.7% | 14.3% | ||
| Q2 24 | 9.7% | 12.4% | ||
| Q1 24 | 8.6% | 6.8% |
净利率RESRVTY
| Q4 25 | -0.7% | 12.7% | ||
| Q3 25 | 2.9% | 6.7% | ||
| Q2 25 | 2.4% | 7.5% | ||
| Q1 25 | 3.6% | 6.4% | ||
| Q4 24 | 3.8% | 13.0% | ||
| Q3 24 | 5.6% | 13.8% | ||
| Q2 24 | 8.9% | 8.0% | ||
| Q1 24 | 7.3% | 4.0% |
每股收益（稀释后）RESRVTY
| Q4 25 | $-0.02 | $0.86 | ||
| Q3 25 | $0.06 | $0.40 | ||
| Q2 25 | $0.05 | $0.46 | ||
| Q1 25 | $0.06 | $0.35 | ||
| Q4 24 | $0.06 | $0.77 | ||
| Q3 24 | $0.09 | $0.77 | ||
| Q2 24 | $0.15 | $0.45 | ||
| Q1 24 | $0.13 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $210.0M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.1B | $7.3B |
| 总资产 | $1.5B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RESRVTY
| Q4 25 | $210.0M | $919.9M | ||
| Q3 25 | $163.5M | $931.4M | ||
| Q2 25 | $162.1M | $991.8M | ||
| Q1 25 | $326.7M | $1.1B | ||
| Q4 24 | $326.0M | $1.2B | ||
| Q3 24 | $276.9M | $1.2B | ||
| Q2 24 | $261.5M | $2.0B | ||
| Q1 24 | $212.2M | $1.7B |
股东权益RESRVTY
| Q4 25 | $1.1B | $7.3B | ||
| Q3 25 | $1.1B | $7.4B | ||
| Q2 25 | $1.1B | $7.6B | ||
| Q1 25 | $1.1B | $7.6B | ||
| Q4 24 | $1.1B | $7.7B | ||
| Q3 24 | $1.1B | $7.9B | ||
| Q2 24 | $1.1B | $7.9B | ||
| Q1 24 | $1.0B | $7.8B |
总资产RESRVTY
| Q4 25 | $1.5B | $12.2B | ||
| Q3 25 | $1.5B | $12.1B | ||
| Q2 25 | $1.5B | $12.4B | ||
| Q1 25 | $1.3B | $12.4B | ||
| Q4 24 | $1.4B | $12.4B | ||
| Q3 24 | $1.3B | $12.8B | ||
| Q2 24 | $1.3B | $13.4B | ||
| Q1 24 | $1.3B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $61.9M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $31.2M | $161.8M |
| 自由现金流率自由现金流/营收 | 7.3% | 21.0% |
| 资本支出强度资本支出/营收 | 7.2% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $52.9M | $509.4M |
8季度趋势，按日历期对齐
经营现金流RESRVTY
| Q4 25 | $61.9M | $182.0M | ||
| Q3 25 | $46.5M | $138.5M | ||
| Q2 25 | $53.1M | $134.3M | ||
| Q1 25 | $39.9M | $128.2M | ||
| Q4 24 | $94.2M | $174.2M | ||
| Q3 24 | $70.7M | $147.9M | ||
| Q2 24 | $127.9M | $158.6M | ||
| Q1 24 | $56.6M | $147.6M |
自由现金流RESRVTY
| Q4 25 | $31.2M | $161.8M | ||
| Q3 25 | $4.1M | $120.0M | ||
| Q2 25 | $10.0M | $115.5M | ||
| Q1 25 | $7.6M | $112.2M | ||
| Q4 24 | $53.7M | $149.8M | ||
| Q3 24 | $19.1M | $125.6M | ||
| Q2 24 | $52.9M | $136.6M | ||
| Q1 24 | $3.8M | $129.7M |
自由现金流率RESRVTY
| Q4 25 | 7.3% | 21.0% | ||
| Q3 25 | 0.9% | 17.2% | ||
| Q2 25 | 2.4% | 16.0% | ||
| Q1 25 | 2.3% | 16.9% | ||
| Q4 24 | 16.0% | 20.5% | ||
| Q3 24 | 5.6% | 18.4% | ||
| Q2 24 | 14.5% | 19.7% | ||
| Q1 24 | 1.0% | 20.0% |
资本支出强度RESRVTY
| Q4 25 | 7.2% | 2.6% | ||
| Q3 25 | 9.5% | 2.6% | ||
| Q2 25 | 10.2% | 2.6% | ||
| Q1 25 | 9.7% | 2.4% | ||
| Q4 24 | 12.1% | 3.4% | ||
| Q3 24 | 15.3% | 3.3% | ||
| Q2 24 | 20.6% | 3.2% | ||
| Q1 24 | 14.0% | 2.7% |
现金转化率RESRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | 3.59× | 2.97× | ||
| Q2 25 | 5.23× | 2.49× | ||
| Q1 25 | 3.31× | 3.03× | ||
| Q4 24 | 7.38× | 1.84× | ||
| Q3 24 | 3.76× | 1.57× | ||
| Q2 24 | 3.95× | 2.87× | ||
| Q1 24 | 2.06× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RES
| Technical Service | $405.2M | 95% |
| Other | $8.8M | 2% |
| Nitrogen | $6.6M | 2% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
